Dr. Reddy's Laboratories
125 hedge funds and large institutions have $651M invested in Dr. Reddy's Laboratories in 2018 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 42 increasing their positions, 39 reducing their positions, and 33 closing their positions.
154% more call options, than puts
Call options by funds: $650K | Put options by funds: $256K
8% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 39
1% less capital invested
Capital invested by funds: $655M → $651M (-$4.16M)
4.31% less ownership
Funds ownership: 61.26% → 56.95% (-4.3%)
9% less funds holding
Funds holding: 137 → 125 (-12)
36% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Grantham, Mayo, Van Otterloo & Co (GMO)
Boston,
Massachusetts
|
+$11.6M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$7.02M |
| 3 |
Renaissance Technologies
New York
|
+$7M |
| 4 |
BlackRock
New York
|
+$5.87M |
| 5 |
SGA
Sector Gamma AS
Oslo,
Norway
|
+$5.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
-$16.7M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$9.21M |
| 3 |
Two Sigma Investments
New York
|
-$8.84M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.54M |
| 5 |
Goldman Sachs
New York
|
-$8.01M |
RDY Hedge Fund Activity: Q3 2018 in Review
125 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Dr. Reddy's Laboratories (RDY) for Q3 2018, worth a combined $651M — down 0.63% from $655M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of RDY and 21 opened new positions — a net loss of 12 holders — while 39 trimmed existing stakes and 42 added.
The largest buyer was Grantham, Mayo, Van Otterloo & Co (GMO), adding an estimated $11.6M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $16.7M sold.
- 125 institutional investors held Dr. Reddy's Laboratories (RDY) as of Q3 2018, down from 137 in Q2 2018.
- Funds reported $651M of Dr. Reddy's Laboratories stock for Q3 2018, down 0.63% quarter-over-quarter.
- 21 funds opened new Dr. Reddy's Laboratories positions in Q3 2018 and 33 closed out, a net change of -12 holders.
- The largest Dr. Reddy's Laboratories buyer in Q3 2018 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $11.6M added.
- The largest Dr. Reddy's Laboratories seller in Q3 2018 was Marshall Wace North America, an estimated $16.7M sold.
Based on aggregated 13F filings for Q3 2018.